South Africa detects new coronavirus variant, still studying its mutations | Inquirer News
Close  

South Africa detects new coronavirus variant, still studying its mutations

/ 11:54 AM August 31, 2021
south africa vaccination

People queue outside a coronavirus disease (COVID-19) vaccination centre as the country opens vaccinations for everyone 18 years old and above in Cape Town, South Africa, August 20, 2021. REUTERS FILE PHOTO

JOHANNESBURG — South African scientists have detected a new coronavirus variant with multiple mutations but are yet to establish whether it is more contagious or able to overcome the immunity provided by vaccines or prior infection.

The new variant, known as C.1.2, was first detected in May and has now spread to most South African provinces and to seven other countries in Africa, Europe, Asia and Oceania, according to research which is yet to be peer-reviewed.

ADVERTISEMENT

It contains many mutations associated in other variants with increased transmissibility and reduced sensitivity to neutralizing antibodies, but they occur in a different mix and scientists are not yet sure how they affect the behavior of the virus. Laboratory tests are underway to establish how well the variant is neutralized by antibodies.

South Africa was the first country to detect the Beta variant, one of only four labelled “of concern” by the World Health Organization (WHO).

FEATURED STORIES

Beta is believed to spread more easily than the original version of the coronavirus that causes COVID-19, and there is evidence vaccines work less well against it, leading some countries to restrict travel to and from South Africa.

Pandemic ‘far from over’

Richard Lessells, an infectious disease specialist and one of the authors of the research on C.1.2, said its emergence tells us “this pandemic is far from over and that this virus is still exploring ways to potentially get better at infecting us”.

He said people should not be overly alarmed at this stage and that variants with more mutations were bound to emerge further into the pandemic.

Genomic sequencing data from South Africa show the C.1.2 variant was still nowhere near displacing the dominant Delta variant in July, the latest month for which a large number of samples was available.

In July C.1.2 accounted for 3% of samples versus 1% in June, whereas Delta accounted for 67% in June and 89% in July.

Delta is the fastest and fittest variant the world has encountered, and it is upending assumptions about COVID-19 even as nations loosen restrictions and reopen their economies.

ADVERTISEMENT

Lessells said C.1.2 may have more immune evasion properties than Delta, based on its pattern of mutations, and that the findings had been flagged to the WHO.

A spokesman for South Africa’s health department declined to comment on the research.

South Africa’s COVID-19 vaccination campaign got off to a slow start, with only around 14% of its adult population fully vaccinated so far.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Coronavirus Variants, COVID-19, Health, South Africa
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2021 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.